Resistance to Antibody-Drug Conjugate

  • Jessica HochbergEmail author
  • Sarah Alexander
Part of the Resistance to Targeted Anti-Cancer Therapeutics book series (RTACT, volume 21)


Immune therapies have shown significant efficacy in the treatment of pediatric lymphomas. Monoclonal antibodies, whether naked or conjugated have emerged as an attractive option for targeted therapy while minimizing toxicities. Monoclonal antibodies conjugated to small molecule drugs were developed as a way to combine highly potent agents with tumor specificity. Current challenges include careful selection of tumor targets, the management of potential toxicities, identification of ideal patient selection and therapy regimens, and a better understanding of antibody-drug conjugates (ADC) mechanisms of action and resistance. The right combination is critical for a successful ADC. Mechanisms of resistance to ADCs can be inherited to the ADC or acquired by the host environment and can developed against each of the individual components of the ADC. Given the rational design of ADCs, there is the ability to modify each of the components to develop improved agents that can overcome resistance.


Pediatrics Lymphoma Antibody Conjugates Resistance Immunotherapy 



Doxorubicin, Bleomycin, Vinblastine, Dacarbazine


Antibody-Drug Conjugate


Antibody Dependent Cellular Cytotoxicity




Activated Tyrosine Kinase


Anaplastic Large Cell Lymphoma


Acute Lymphoblastic Leukemia


Acute Myeloid Leukemia


Doxorubicin, Vinblastine, Dacarbazine


Brentuximab Vedotin


Confidence Interval


Children’s Oncology Group


Complete Response


Diffuse Large B-Cell Lymphoma


Food and Drug Administration


Gemtuzumab Ozogamicin


Hodgkin Lymphoma


Hazard Ratio


Inotuzumab Ozogamicin


Monoclonal Antibody


Mycosis Fungoides


Monomethylauristatin E


Non-Hodgkin Lymphoma


Objective Response


Primary cutaneous Anaplastic Large Cell Lymphoma


Progression-Free Survival


Response Rate


Disclosure of Conflict of Interest

No potential conflicts of interest were disclosed.


  1. 1.
    Panowski S, Bhakta S, Raab H, Polakis P, Junutula JR. Site-specific antibody drug conjugates for cancer therapy. MAbs. 2014;6(1):34–45.CrossRefGoogle Scholar
  2. 2.
    Dan N, Setua S, Kashyap VK, Khan S, Jaggi M, Yallapu MM, et al. Antibody-drug conjugates for Cancer therapy: chemistry to clinical implications. Pharmaceuticals (Basel). 2018;11(2)Google Scholar
  3. 3.
    Lambert JM, Berkenblit A. Antibody-drug conjugates for Cancer treatment. Annu Rev Med. 2018;69:191–207.CrossRefGoogle Scholar
  4. 4.
    Wang X, Mathieu M, Brezski RJ. IgG Fc engineering to modulate antibody effector functions. Protein Cell. 2018;9(1):63–73.CrossRefGoogle Scholar
  5. 5.
    Beck A, Goetsch L, Dumontet C, Corvaia N. Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov. 2017;16(5):315–37.CrossRefGoogle Scholar
  6. 6.
    Garcia-Alonso S, Ocana A, Pandiella A. Resistance to antibody-drug conjugates. Cancer Res. 2018;78(9):2159–65.CrossRefGoogle Scholar
  7. 7.
    Herrera AF, Molina A. Investigational antibody-drug conjugates for treatment of B-lineage malignancies. Clin Lymphoma Myeloma Leuk. 2018;18(7):452–68 e4.CrossRefGoogle Scholar
  8. 8.
    Pro B, Advani R, Brice P, Bartlett NL, Rosenblatt JD, Illidge T, et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol. 2012;30(18):2190–6.CrossRefGoogle Scholar
  9. 9.
    Connors JM, Radford JA. Brentuximab Vedotin for stage III or IV Hodgkin’s lymphoma. N Engl J Med. 2018;378(16):1560–1.PubMedGoogle Scholar
  10. 10.
    Adcetris. (brentuximab vedotin) [package insert]; FDA reference ID: 4237000; Seattle genetics, Bothell. 2011.Google Scholar
  11. 11.
    Jacobsen ED, Sharman JP, Oki Y, Advani RH, Winter JN, Bello CM, et al. Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression. Blood. 2015;125(9):1394–402.CrossRefGoogle Scholar
  12. 12.
    Locatelli F, Neville KA, Rosolen A, Landman-Parker J, Aladjidi N, Beishuizen A, Daw S, Gore L, Franklin AR, Fasanmade A, Wang J, Sachs J. Phase 1/2 study of Brentuximab Vedotin in pediatric patients with relapsed or refractory (R/R) Hodgkin Lymphoma (HL) or Systemic Anaplastic Large-Cell Lymphoma (sALCL): preliminary phase 2 data for Brentuximab Vedotin 1.8 mg/kg in the HL study arm. Blood. 2013;122(21):4378.Google Scholar
  13. 13.
    Goy A, Forero A, Wagner-Johnston N, Christopher Ehmann W, Tsai M, Hatake K, et al. A phase 2 study of inotuzumab ozogamicin in patients with indolent B-cell non-Hodgkin lymphoma refractory to rituximab alone, rituximab and chemotherapy, or radioimmunotherapy. Br J Haematol. 2016;174(4):571–81.CrossRefGoogle Scholar
  14. 14.
    Fayad L, Offner F, Smith MR, Verhoef G, Johnson P, Kaufman JL, et al. Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab. J Clin Oncol. 2013;31(5):573–83.CrossRefGoogle Scholar
  15. 15.
    Dang NH, Ogura M, Castaigne S, Fayad LE, Jerkeman M, Radford J, et al. Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab versus chemotherapy plus rituximab for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma. Br J Haematol. 2018;182(4):583–6.CrossRefGoogle Scholar
  16. 16.
    Younes A, Kim S, Romaguera J, Copeland A, Farial Sde C, Kwak LW, et al. Phase I multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed/refractory B-cell lymphoma. J Clin Oncol. 2012;30(22):2776–82.CrossRefGoogle Scholar
  17. 17.
    Coiffier B, Thieblemont C, de Guibert S, Dupuis J, Ribrag V, Bouabdallah R, et al. A phase II, single-arm, multicentre study of coltuximab ravtansine (SAR3419) and rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma. Br J Haematol. 2016;173(5):722–30.CrossRefGoogle Scholar
  18. 18.
    Moskowitz CH, Fanale MA, Shah BD, Advani RH, Chen R, Kim S, Kostic A, Liu T, Peng J, Forero-Torres A. A phase 1 study of Denintuzumab Mafodotin (SGN-CD19A) in relapsed/Refactory B-lineage non-Hodgkin lymphoma. Blood. 2015;126(23):182.Google Scholar
  19. 19.
    Kahl BS, Hamadani M, Caimi P, Carlo-Stella C, Reid E, Feingold J, Ardeshna KM, et al. Encouraging early results from the first in-human clinical trial of ADCT-402 (Loncastuximab Tesirine), a novel Pyrrolobenzodiazepine-based antibody drug conjugate, in relapsed/refractory B-cell lineage non-Hodgkin lymphoma. Blood. 2017;130:149.Google Scholar
  20. 20.
    Advani RH, Lebovic D, Chen A, Brunvand M, Goy A, Chang JE, et al. Phase I study of the anti-CD22 antibody-drug conjugate Pinatuzumab Vedotin with/without rituximab in patients with relapsed/refractory B-cell non-Hodgkin lymphoma. Clin Cancer Res. 2017;23(5):1167–76.CrossRefGoogle Scholar
  21. 21.
    Palanca-Wessels MC, Czuczman M, Salles G, Assouline S, Sehn LH, Flinn I, et al. Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study. Lancet Oncol. 2015;16(6):704–15.CrossRefGoogle Scholar
  22. 22.
    Tilly H, Sharman J, Bartlett N, Morschhauser F, Haioun C, Munoz J, et al. POLA-R-CHP: Poloatuzumab Vedotin combined with rituximab, cyclophosphamide, cyclophosphamide, doxorubicin, prednisone for patients with previously untreated diffuse large B cell lymphoma. Hematol Oncol. 2017;35(52):90–2.CrossRefGoogle Scholar
  23. 23.
    Phillips T, Brunvand M, Chen A, Press O, Essell J, Chiappella A, Diefenbach C, Jones S, Hirata J, Flinn IW. Polatuzumab Vedotin combined with Obinutuzumab for patients with relapsed or refractory non-Hodgkin lymphoma: preliminary safety and clinical activity of a phase Ib/II study. Blood. 2016;128(22):622.Google Scholar
  24. 24.
    Kalim M, Chen J, Wang S, Lin C, Ullah S, Liang K, et al. Intracellular trafficking of new anticancer therapeutics: antibody-drug conjugates. Drug Des Devel Ther. 2017;11:2265–76.CrossRefGoogle Scholar
  25. 25.
    Linenberger ML, Hong T, Flowers D, Sievers EL, Gooley TA, Bennett JM, et al. Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin. Blood. 2001;98(4):988–94.CrossRefGoogle Scholar
  26. 26.
    Yu M, Ocana A, Tannock IF. Reversal of ATP-binding cassette drug transporter activity to modulate chemoresistance: why has it failed to provide clinical benefit? Cancer Metastasis Rev. 2013;32(1–2):211–27.CrossRefGoogle Scholar
  27. 27.
    Cianfriglia M. The biology of MDR1-P-glycoprotein (MDR1-Pgp) in designing functional antibody drug conjugates (ADCs): the experience of gemtuzumab ozogamicin. Ann Ist Super Sanita. 2013;49(2):150–68.PubMedGoogle Scholar
  28. 28.
    Takeshita A, Shinjo K, Yamakage N, Ono T, Hirano I, Matsui H, et al. CMC-544 (inotuzumab ozogamicin) shows less effect on multidrug resistant cells: analyses in cell lines and cells from patients with B-cell chronic lymphocytic leukaemia and lymphoma. Br J Haematol. 2009;146(1):34–43.CrossRefGoogle Scholar
  29. 29.
    Rosen DB, Harrington KH, Cordeiro JA, Leung LY, Putta S, Lacayo N, et al. AKT signaling as a novel factor associated with in vitro resistance of human AML to gemtuzumab ozogamicin. PLoS One. 2013;8(1):e53518.CrossRefGoogle Scholar
  30. 30.
    Haag P, Viktorsson K, Lindberg ML, Kanter L, Lewensohn R, Stenke L. Deficient activation of Bak and Bax confers resistance to gemtuzumab ozogamicin-induced apoptotic cell death in AML. Exp Hematol. 2009;37(6):755–66.CrossRefGoogle Scholar
  31. 31.
    Chen R, Hou J, Nair I, Wu J, Synold T, Kwak L, et al. Inhibition of MDR1 overcomes Brentuximab Vedotin resistance in Hodgkin lymphoma cell line model and is synergistic with Brentuximab Vedotin in mouse xenograft model. Blood. 2016;128(22):752.Google Scholar
  32. 32.
    Al-Rohil RN, Torres-Cabala CA, Patel A, Tetzlaff MT, Ivan D, Nagarajan P, et al. Loss of CD30 expression after treatment with brentuximab vedotin in a patient with anaplastic large cell lymphoma: a novel finding. J Cutan Pathol. 2016;43(12):1161–6.CrossRefGoogle Scholar
  33. 33.
    Arai H, Furuichi S, Nakamura Y, Ichikawa M, Mitani K. ALK-negative anaplastic large cell lymphoma with loss of CD30 expression during treatment with brentuximab vedotin. Rinsho Ketsueki. 2016;57(5):634–7.PubMedGoogle Scholar
  34. 34.
    Nielson C, Fischer R, Fraga G, Aires D. Loss of CD30 expression in anaplastic large cell lymphoma following Brentuximab therapy. J Drugs Dermatol. 2016;15(7):894–5.PubMedGoogle Scholar
  35. 35.
    Chen R, Hou J, Newman E, Kim Y, Donohue C, Liu X, et al. CD30 downregulation, MMAE resistance, and MDR1 upregulation are all associated with resistance to Brentuximab Vedotin. Mol Cancer Ther. 2015;14(6):1376–84.CrossRefGoogle Scholar
  36. 36.
    Zhao WL, Daneshpouy ME, Mounier N, Briere J, Leboeuf C, Plassa LF, et al. Prognostic significance of bcl-xL gene expression and apoptotic cell counts in follicular lymphoma. Blood. 2004;103(2):695–7.CrossRefGoogle Scholar
  37. 37.
    Dornan D, Bennett F, Chen Y, Dennis M, Eaton D, Elkins K, et al. Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma. Blood. 2009;114(13):2721–9.CrossRefGoogle Scholar
  38. 38.
    Adem YT, Schwarz KA, Duenas E, Patapoff TW, Galush WJ, Esue O. Auristatin antibody drug conjugate physical instability and the role of drug payload. Bioconjug Chem. 2014;25(4):656–64.CrossRefGoogle Scholar
  39. 39.
    Gerber HP, Sapra P, Loganzo F, May C. Combining antibody-drug conjugates and immune-mediated cancer therapy: what to expect? Biochem Pharmacol. 2016;102:1–6.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Division of Hematology, Oncology & Stem Cell Transplant, Maria Fareri Children’s Hospital at Westchester Medical CenterNew York Medical CollegeValhallaUSA
  2. 2.Division of Haematology/OncologyThe Hospital for Sick ChildrenTorontoCanada

Personalised recommendations